Eulexin (Flutamide) - Indications and Dosage

INDICATIONS AND USAGE

EULEXIN Capsules are indicated for use in combination with LHRH agonists for the management of locally confined Stage B₂-C and Stage D₂ metastatic carcinoma of the prostate.

Stage B₂-C Prostatic Carcinoma

Treatment with EULEXIN Capsules and the goserelin acetate implant should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy.

Stage D₂ Metastatic Carcinoma

To achieve benefit from treatment, EULEXIN Capsules should be initiated with the LHRH-agonist and continued until progression.

DOSAGE AND ADMINISTRATION

The recommended dosage is 2 capsules 3 times a day at 8-hour intervals for a total daily dose of 750 mg.

HOW SUPPLIED

EULEXIN Capsules, 125 mg, are available as opaque, two-toned brown capsules, imprinted with "Schering 525". They are supplied as follows:

NDC 0085-0525-05 - Bottles of 500
NDC 0085-0525-03 - Unit Dose packages of 100 (10 × 10's)
NDC 0085-0525-06 - Bottles of 180

Store between 2° and 30°C (36° and 86°F).

Protect the Unit Dose packages from excessive moisture.

Rev. 12/00

18822440T
B-16887692

Copyright © 1989, 1996, 1999, Schering Corporation. All rights reserved.